Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028: Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan

News provided by

Dec 02, 2019, 17:45 ET

DUBLIN, Dec. 2, 2019 /PRNewswire/ -- The "Immune Thrombocytopenia (ITP) - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Immune thrombocytopenia (ITP)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ITP in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Most of children with newly diagnosed ITP will develop chronic disease. Because of the high impact of ITP on a child's everyday life and activities, as well as to decide whether treatment has to be instituted to influence the clinical course of ITP, it is of clinical significance if the course of the disease could be predicted at time of diagnosis.

Our forecasting model has defined the prevalent population of Chronic Immune Thrombocytopenia (ITP) in children & adults. Chronic ITP patient inclusive of both primary ITP and secondary ITP. Approximately 70-75% of patient are refractory to first line therapies (corticosteroids/IVIG & others) and take second line therapies. As per the analysis, we have found that approximately 60-65% patients are refractory to second line treatment and take third line treatment.

Immune thrombocytopenia (ITP) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, Total Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, and Gender-specific Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM) scenario of Immune thrombocytopenia (ITP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The total diagnosed cases of Immune thrombocytopenia (ITP) were found out to be approximately 147,174 in 2017, in the 7MM. The number of Immune thrombocytopenia (ITP) cases in the 7MM is expected to increase during the study period of 2017-2028.

Immune thrombocytopenia (ITP) Drug Chapters

Broadly, two categories of agents are available for the treatment of ITP: those that rapidly and transiently interfere with the process of platelet destruction for management of acute bleeding or bleeding risk (front-line therapies), and those with the potential to provide a more durable improvement in the platelet count (second-line therapies).

The first-line options for therapy of ITP disease includes use of corticosteroids, IVIG, and anti-D immunoglobulin. There are three classes of second-line therapies that includes: splenectomy, rituximab, and the thrombopoietin receptor agonists (TPO-RA).

The US Food and Drug Administration (FDA) have approved three TPO-RA therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). However for Europe and Japan, only two TPO-RAs is approved i.e. nplate and promacta. Promacta and nplate are going to lose their patent in 2020 in the US, and in Europe and Japan, nplate will lose the patent in 2019 while promacta will lose patent in 2025.

According to this research's analysis, Doptelet will generate USD 15.50 million in 2019 in the United States. Promacta was approved in Japan in 2010, for the treatment of ITP in adults. While, Nplate was approved in japan in 2011 for the treatment of ITP in adults. The market of both the drugs will experience a decline due to their patent expiry in the year, 2019 and 2025, respectively.

Immune thrombocytopenia (ITP) Market Outlook

According to this research, the market of Immune thrombocytopenia (ITP) in 7MM was found to be approximately USD 2,678.0 million in 2017. Among the EU5 countries, in 2017, United Kingdom had the highest market size with approximately USD 262.00 million, while Spain had the lowest market size for Immune thrombocytopenia (ITP) with approximately USD 121.00 million.

Immune thrombocytopenia (ITP) Drugs Uptake

The dynamics of Immune thrombocytopenia (ITP) market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. The therapies which are under development for the treatment of ITP are BT595 (Biotest); UCB7665 (UCB Biopharma) and ARGX-113 (Argenx BVBA). With the expected launch of upcoming therapies, BT595 (Biotest) in 2021; Rozanolixizumab (UCB7665: UCB Biopharma) in and Efgartigimod (ARGX-113: Argenx BVBA) in 2023, the market will experience a significant growth.

Diagnostic Guidelines of Immune Thrombocytopenia

2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
The American Society of Hematology 2011 evidence-based practice guideline for Immune Thrombocytopenia
Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI

Marketed Drugs
Key Cross Competition
Octagam: Octapharma USA

Product Description
Regulatory Milestones
Safety and Efficacy of Octagam
Side effects of Octagam
Product Profile

Nplate (AMG-531): Amgen
Privigen: CSL Behring
Rhophylac: CSL Behring
Doptelet (Avatrombopag): Dova Pharmaceuticals
Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
Rituximab: Zenyaku Kogyo/Biogen Idec
Promacta (eltrombopag): Novartis
Gammaplex: Bio Products Laboratory's
Takecab: Takeda Pharmaceutical Company Limited
Nexium Capsules: AstraZeneca

Emerging Drugs
Key Cross Competition
BT-595: Biotest

Drug Description
Other Development Activities
Advantages and Disadvantages
Clinical Development
Clinical Trials Information
Product Profile

GC5107A: GC Pharma
LIV-Gamma SN Inj.: SK Plasma
Hetrombopag Olamine: Jiangsu HengRui Medicine
Efgartigimod (ARGX-113): Argenx
SKI-O-703: Genosco (a US-based subsidiary of Korean bio company Oscotec)
KZR-616: Kezar Life Sciences
Rozanolixizumab: UCB Biopharma
BMS-986004 (Letolizumab): Bristol-Myers Squibb
PRN-1008: Principia Biopharma
PRTX-100: Protalex

Companies Mentioned

Octapharma USA
Amgen
CSL Behring
Dova Pharmaceuticals
Rigel Pharmaceuticals
Zenyaku Kogyo/Biogen Idec
Novartis
Bio Products Laboratory's
Takeda Pharmaceutical Company Limited
AstraZeneca
Biotest
GC Pharma
SK Plasma
Jiangsu HengRui Medicine
Argenx
Genosco
Kezar Life Sciences
UCB Biopharma
Bristol-Myers Squibb
Principia Biopharma
Protalex

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ulvyl4

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets